Focus on lymphomas

Cancer Cell. 2002 Nov;2(5):363-6. doi: 10.1016/s1535-6108(02)00178-2.
No abstract available

Publication types

  • Review

MeSH terms

  • Alemtuzumab
  • Anti-Bacterial Agents / therapeutic use
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Neoplasm / therapeutic use
  • Antineoplastic Agents / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Chromosome Aberrations
  • Cyclophosphamide / therapeutic use
  • Doxorubicin / therapeutic use
  • Etoposide / therapeutic use
  • Gene Expression
  • Humans
  • Interleukin-2 / therapeutic use
  • Lymphoma / diagnosis
  • Lymphoma / genetics*
  • Lymphoma / therapy
  • Prednisone / therapeutic use
  • Risk Factors
  • Rituximab
  • Survival
  • Vaccines / therapeutic use
  • Vincristine / therapeutic use

Substances

  • Anti-Bacterial Agents
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antibodies, Monoclonal, Murine-Derived
  • Antibodies, Neoplasm
  • Antineoplastic Agents
  • Interleukin-2
  • Vaccines
  • Alemtuzumab
  • Rituximab
  • Vincristine
  • Etoposide
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone

Supplementary concepts

  • CHOP protocol
  • EPOCH protocol